Bomedemstat
Bomedmestat (United States Adopted Name, USAN; IUPAC name ''N''-[(2''S'')-5-(1''R'',2''S'')-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide) is an investigational drug under development by Imago BioSciences for the treatment of myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera, Primary myelofibrosis, myelofibrosis and small-cell lung cancer. History Bomedmestat, also known as IMG-7289 or MRK3543, the bis-tosylate salt of IMG-241 MRK3543, was invented by John McCall, Hugh Young Rienhoff, Jr. and Michael Clare in 2014. The original composition-of-matter patent application was filed in 2014. and issued as US patent US-20150299151-A1 followed by other issued patents on polymorphs, Salt (chemistry), salt forms and methods of Manufacturing, manufacture. Merck (Merck Sharp and Dohme) acquired Imago BioSciences with the rights to develop bomedemstat in January 2023. Mechanism of action Bo ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]